Financial Performance - The company's operating revenue for 2024 was CNY 483,409,860, representing a 1.57% increase compared to CNY 475,956,542 in 2023[17]. - Net profit attributable to shareholders decreased by 48.51% to CNY 33,648,492.2 in 2024 from CNY 65,353,285.6 in 2023[17]. - The net profit after deducting non-recurring gains and losses fell by 49.56% to CNY 29,823,788.6 in 2024 compared to CNY 59,128,884.6 in 2023[17]. - The net cash flow from operating activities decreased by 18.85% to CNY 52,857,477.4 in 2024 from CNY 65,133,208.7 in 2023[17]. - Basic and diluted earnings per share dropped by 60.69% to CNY 0.6 in 2024 from CNY 1.5265 in 2023[17]. - Total assets increased by 57.75% to CNY 1,079,011,970.7 at the end of 2024 from CNY 683,982,603.0 at the end of 2023[17]. - Net assets attributable to shareholders rose by 73.61% to CNY 826,026,725.80 at the end of 2024 from CNY 475,802,407.0 at the end of 2023[17]. - The company achieved operating revenue of 483.41 million yuan, a year-on-year increase of 1.57%[55]. - The company's net profit attributable to shareholders was 33.65 million yuan, a decrease of 48.51% compared to the previous year[55]. - The precision drug delivery device business generated revenue of 36.76 million yuan, a decrease of 36.17% year-on-year due to fluctuations in customer orders[56]. - The micro special motor and components business revenue reached 409.94 million yuan, an increase of 7.13% year-on-year[56]. Dividend Distribution - The company plans to distribute a cash dividend of 3.5 RMB per 10 shares to all shareholders, based on a total of 57.0835 million shares[4]. - The company distributed cash dividends of 5.25 CNY per 10 shares, totaling 29,968,837.50 CNY (including tax) based on a total share capital of 57,083,500 shares[167]. - The cash dividend distribution accounted for 100% of the total profit distribution amount[168]. Business Operations and Strategy - The company has subsidiaries including Jiangsu Delphi Medical Equipment Co., Ltd. and Huayang Intelligent Equipment (Suqian) Co., Ltd.[10]. - The company is focusing on the development of precision drug delivery devices as an important innovation direction[24]. - The company is actively exploring new application areas, including automotive, kitchen appliances, and security monitoring, to drive business growth[39]. - The company aims to strengthen its core business in precision motors and expand into the medical device sector, targeting to become an industry leader[98]. - A plan for automation and intelligent production transformation of precision motors is set for 2024, aiming to reduce costs and enhance product quality[100]. - The company is committed to environmental protection, utilizing distributed photovoltaic power generation to optimize electricity structure and reduce costs[185]. Market Trends and Demand - The biopharmaceutical market is driving demand for precision drug delivery devices, particularly injection pens, as chronic diseases become more prevalent[30]. - The market for growth hormone treatments is significant, with approximately 540,000 children in China potentially benefiting from such therapies, thereby increasing the demand for injection pens[31]. - In 2024, the global diabetes patient population is expected to reach 589 million, with China accounting for about 148 million, indicating a substantial market for diabetes treatment devices[32]. - The demand for micro-special motors in air conditioning is increasing, with new models requiring up to 8 motors per unit due to advancements in air delivery technology[27]. - The central air conditioning market is expanding, with each indoor unit typically requiring 8 motors, significantly boosting the demand for micro-special motors[27]. Research and Development - The company has established a dual-driven R&D system focusing on "pre-research + transformation," covering advanced fields such as smart micro-injection and high-concentration drug infusion systems[42]. - Key R&D focuses for 2025 include breakthroughs in core technologies for frameless motors and the development of high-viscosity drug delivery devices[101]. - The company has completed the development of a stepper motor with extended voltage application, enhancing product competitiveness across various industries such as industrial automation and medical devices[67]. - The company has developed innovative products, including a gear box component and a new type of ultrasonic piezoelectric actuator motor, enhancing its competitive edge[38]. Governance and Management - The company has a board of directors with a mix of independent and non-independent members, including 3 independent directors[136]. - The company has established a performance evaluation system for directors and senior management to ensure fairness and transparency in the incentive mechanism[120]. - The company maintains independence in assets, personnel, finance, and operations from its controlling shareholder, ensuring a complete business system[125]. - The company has a dedicated financial department with independent financial decision-making capabilities and does not share bank accounts with its controlling shareholder[127]. - The company emphasizes social responsibility and actively communicates with stakeholders to balance interests among shareholders, employees, and society[121]. Financial Management and Compliance - The company has established a comprehensive internal control system in accordance with the "Basic Norms for Enterprise Internal Control," effectively preventing operational risks and promoting the achievement of internal control objectives[171]. - The internal control audit report issued a standard unqualified opinion, confirming the effectiveness of financial reporting internal controls[177]. - The company has implemented targeted compliance training for middle management and employees to enhance risk prevention awareness and ensure effective execution of internal control systems[172]. - The company is committed to maintaining transparency in its financial reporting, with regular updates on its financial performance and strategic initiatives[158]. Investor Relations - The company has a dedicated investor relations contact, Wu Wenjing, for shareholder inquiries[14]. - The company maintains open communication channels with investors, ensuring timely responses to inquiries and protecting the rights of minority shareholders[181]. - The company has engaged in multiple investor communications, discussing its drug delivery device business and future strategies[110]. Risk Management - Market expansion risks include reliance on existing markets and the need for effective new product development and sales strategies[105]. - Raw material price fluctuations pose a risk to profit margins, with strategies in place to optimize supply chain management and reduce costs[107]. - Rising labor costs are anticipated due to increased living standards and inflation, prompting the company to focus on automation and production efficiency improvements[109]. Sustainability and Social Responsibility - The company has been recognized as a "2024 Green Factory" in Changzhou for its efforts in sustainable practices[179]. - The company actively participates in social responsibility initiatives, including public recruitment and charitable activities[186]. - The company emphasizes employee rights protection, focusing on a comprehensive employee care system and a fair compensation management system[182].

近日，江苏华阳智能装备股份有限公司（以下简称"华阳智能"）发布公告，宣布终止收购贵州全安密灵科技有限公司不低于51%股权的重大资产重组事项。 然而，交易各方虽对本次重大资产重组交易方案进行了多次协商，并对全安密灵相关技术在智能控制、模组电机等领域的应用以及双方的业务协同关系进行 了充分论证，但最终未能就交易最终方案达成一致。 4月10日，经充分论证及友好协商，各方同意终止本次重大资产重组事项，华阳智能与全安密灵及其主要股东签署了《终止协议》。 华阳智能表示，终止本次重大资产重组不会对现有生产经营活动、财务状况和战略发展造成重大不利影响，不存在损害该公司及全体股东尤其是中小股东利 益的情形。根据相关规定，华阳智能承诺自公告披露之日起至少1个月内不再筹划重大资产重组。 2025年1月7日，华阳智能曾披露拟以支付现金的方式，收购全安密灵全部或部分股东持有的不低于51%股权。根据初步研究和测算，交易预计构成《上市公 司重大资产重组管理办法》规定的重大资产重组。该交易不涉及上市公司发行股份，不构成关联交易，也不会导致上市公司控股股东和实际控制人发生变 更。若交易完成，全安密灵将成为华阳智能的控股子公司，纳入合并报表范围 ...

Core Viewpoint - Jiangsu Huayang Intelligent Equipment Co., Ltd. has terminated its major asset restructuring plan to acquire at least 51% of Guizhou Quanan Miling Technology Co., Ltd. due to a lack of agreement on the final transaction scheme [2][3]. Group 1: Termination of Restructuring - The restructuring plan was initially seen as a significant move to expand the company's business footprint but was terminated just three months after its announcement [3]. - On April 11, the company announced the termination after thorough research and friendly negotiations with the relevant parties, signing a termination agreement [3]. - Prior to the termination announcement, the company indicated that the transaction was still in the planning stage and had not yet signed a formal agreement [3]. Group 2: Financial Performance - For the first three quarters of 2024, the company reported a revenue increase of 1.58% year-on-year, but its net profit attributable to shareholders decreased by 47.6% [2][5]. - In the first half of 2024, the company achieved a revenue of 278 million yuan, a year-on-year growth of 3.99%, while the net profit dropped by 39.94% [5]. - In 2023, the company reported a revenue of 476 million yuan, with a year-on-year growth of 2.7%, and a net profit of 65 million yuan, up by 2.92% [5]. Group 3: Business Overview - The company's main business is the research, production, and sales of micro-special motors and components, primarily serving leading home appliance manufacturers [4][6]. - In 2023, the micro-special motor and component business accounted for 80.4% of the company's total revenue, making it a pillar of the business [6]. - The company has also been expanding into other areas, including medical devices and industrial control chips, leveraging its expertise in micro-special motors [7].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301502 证券简称：华阳智能 公告编号：2025-016 江苏华阳智能装备股份有限公司 关于公司终止重大资产重组事项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 自筹划重大资产重组事项以来，公司按照相关法律法规要求，积极组织交易双方以及中介机构稳步推进 本次重大资产重组各项工作。交易各方对本次重大资产重组交易方案进行了多次协商，并对标的公司相 关技术在智能控制、模组电机等领域的应用以及双方的业务协同关系进行了充分论证，但双方未能就交 易最终方案达成一致。为切实维护公司及全体股东利益，经公司充分审慎研究及与相关交易对方友好协 商，同意终止本次重大资产重组事项。 江苏华阳智能装备股份有限公司（以下简称"公司"）于2025年1月7日披露了《关于筹划重大资产重组暨 签署〈合作意向书〉的提示性公告》（公告编号：2025-005），公司拟以支付现金的方式收购贵州全安 密灵科技有限公司（以下简称"标的公司"）全部或部分股东持有的标的公司不低于51%的股权（以下简 称"本次交易"）。为切实维护公司及全体 ...

证券代码：301502 证券简称：华阳智能 公告编号：2025-016 江苏华阳智能装备股份有限公司 关于公司终止重大资产重组事项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏华阳智能装备股份有限公司（以下简称"公司"）于2025年1月7日披露了 《关于筹划重大资产重组暨签署〈合作意向书〉的提示性公告》（公告编号： 2025-005），公司拟以支付现金的方式收购贵州全安密灵科技有限公司（以下简 称"标的公司"）全部或部分股东持有的标的公司不低于51%的股权（以下简称 "本次交易"）。为切实维护公司及全体股东利益，经公司充分审慎研究及与相关 交易对方友好协商，同意终止本次重大资产重组事项并与标的公司及其主要股东 签署了《终止协议》。现将终止本次重大资产重组事项的情况公告如下： 一、本次重大资产重组的基本情况 公司与标的公司及其主要股东签署了《合作意向书》，拟以现金方式收购标 的公司全部或部分股东持有的标的公司不低于51.00%的股权。本次交易完成后， 标的公司将成为上市公司的控股子公司，纳入上市公司合并报表范围。 根据初步研究和测算，本次交易预计构 ...

关于筹划重大资产重组事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 证券代码：301502 证券简称：华阳智能 公告编号：2025-015 江苏华阳智能装备股份有限公司 一、本次重大资产重组的基本情况 公司拟以支付现金的方式收购贵州全安密灵科技有限公司全部或部分股东持 有的标的公司不低于51%的股权，本次交易完成后公司将实现对标的公司的控股 。本次交易不涉及公司发行股份，也不会导致公司控制权的变更。公司已与标的 公司及其主要股东签署了《合作意向书》。具体内容详见公司于2025年1月7日在 1、江苏华阳智能装备股份有限公司（以下简称"公司"）拟以支付现金的 方式收购贵州全安密灵科技有限公司（以下简称"标的公司"）全部或部分股东 持有的标的公司不低于51%的股权（以下简称"本次交易"），本次交易完成后 ，公司将实现对标的公司的控股。本次交易不涉及公司发行股份，也不会导致公 司控制权的变更； 2、本次交易尚处于筹划阶段，公司与标的公司及其主要股东已签署的《合 作意向书》仅为意向性协议，交易各方尚未签署正式的交易协议，具体交易方案 仍在商讨 ...

申 话: 025-85803866 传直: 025-858 北京国枫(南京)律师事务所 关于江苏华阳智能装备股份有限公司 2025 年第一次临时股东大会的 法律意见书 国枫律股字[2025]H0008 号 致: 江苏华阳智能装备股份有限公司（贵公司） 北京国枫(南京)律师事务所(以下简称"本所")接受贵公司的委托,指派律师 出席并见证贵公司 2025 年第一次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》(以下简称"《证券法》")、《上市公司股东大会规则》(以下简 称"《股东大会规则》"）、《律师事务所从事证券法律业务管理办法》(以下简称"《证 券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简 称"《证券法律业务执业规则》")等相关法律、行政法规、规章、规范性文件及《江 苏华阳智能装备股份有限公司章程》(以下简称"《公司章程》")的规定,就本次会 议的召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事 宜,出具本法律意见书。 对本法律意见书的出具,本所律师特作如下声明: 1．本 ...

1.本次股东大会未出现否决议案的情形； 2.本次股东大会未涉及变更以往股东大会决议的情形。 一、会议召开和出席情况 （一）股东大会届次：2025年第一次临时股东大会 证券代码：301502 证券简称：华阳智能 公告编号：2025-014 江苏华阳智能装备股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： （二）会议召集人：公司董事会 （三）会议召开方式：采取现场投票与网络投票相结合的方式。 （四）会议召开时间： 1.现场会议召开时间：2025年3月24日（星期一）下午14:00； 2.网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025年3月24日（星期一）的交易时间，即9:15-9:25，9:30-11:30和13:00-15:00； 通过深圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的具 体时间为：2025年3月24日9:15-15:00任意时间。 （五）现场会议召开地点：江苏省常州经开区潞横路2888号江苏华阳智能 装备股份有限公司会议室 ...

东吴证券股份有限公司 关于江苏华阳智能装备股份有限公司 使用闲置自有资金进行委托理财相关事项的核查意见 东吴证券股份有限公司（以下简称"东吴证券"或"保荐人"）作为江苏 华阳智能装备股份有限公司（以下简称"华阳智能"或"公司"）首次公开发 行股票并在创业板上市及持续督导的保荐人，根据《证券发行上市保荐业务管 理办法》《深圳证券交易所创业板股票上市规则》及《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》等有关规定，对华阳智 能使用闲置自有资金进行委托理财的相关事项进行了审慎核查，具体情况如下： 一、本次使用闲置自有资金进行委托理财的基本情况 1、投资目的 为提高公司资金使用效率，增加投资收益，提升公司盈利能力，为公司和股东 获取更多回报。 2、委托理财主体：公司及全资子公司（合并报表范围内的子公司） 3、投资额度及期限 公司拟使用闲置自有资金不超过人民币1.5亿元(含1.5亿元)进行委托理财，上述 资金额度自2025年第一次临时股东大会通过之日起12个月内可以循环滚动使用，任 一时点的交易金额（含前述投资的收益进行再投资的相关金额）不应超过前述投资 额度。 4、投资品种 公司将按照相 ...

东吴证券股份有限公司 关于江苏华阳智能装备股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 东吴证券股份有限公司（以下简称"东吴证券"或"保荐人"）作为江苏 华阳智能装备股份有限公司（以下简称"华阳智能"或"公司"）首次公开发 行股票并在创业板上市及持续督导的保荐人，根据《证券发行上市保荐业务管 理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 要求》《深圳证券交易所创业板股票上市规则》及《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》等有关规定，对华阳智能 募集资金使用的相关事项进行了审慎核查，具体情况如下： 一、本次募集资金的基本情况 经中国证券监督管理委员会《关于同意江苏华阳智能装备股份有限公司首次 公开发行股票注册的批复》(证监许可[2023]2122 号)同意注册，公司首次公 开发行人民币普通股(A 股)股票1,427.10 万股，每股面值为人民币1.00 元，发行价格 为人民币 28.01 元/股，募集资金总额为人民币 39,973.07 万元，扣除发行费用人 民币 5,457.26 万元(不含增值税金额)后，实际募集资金净额为人民币34 ...